Consensus ICON Public Limited Company

Equities

ICLR

IE0005711209

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 20/06/2025 BST			5-day change	1st Jan Change
146.48 ^USD	+2.13%		+0.56%	-30.15%

05-23	Trump's Tariff Blitz Roils Markets, Targets EU and Apple
05-23	Analyst recommendations: Crowdstrike, AMD, Boeing, Intuit, Okta…

Evolution of the Average Target: ICON Public Limited Company

Evolution of the Target Price: ICON Public Limited Company

Changes in Analyst Recommendations: ICON Public Limited Company

7dc7064c3721a.bJznqcm13WpD1_RuG1tGRfQbNCRHVpH--QzXD-qXuZg.WfSo-fjBuCR6gbxecjgICYxoWBYAN9StiF6afJ7d39Ml6J7TjfeZGAXkxA~c9ff6e9ad9b186d06a1cf3d595ec907a

Analysts' recommendations: ICON Public Limited Company

Analyst recommendations: Crowdstrike, AMD, Boeing, Intuit, Okta…	05-23
Truist Securities Adjusts Price Target on ICON to $190 From $208, Keeps Buy Rating	05-05	MT
Deutsche Bank Adjusts ICON Price Target to $200 From $235, Maintains Buy Rating	05-01	MT
Analyst recommendations: Meta Platforms, Progressive, Equifax, SBA Communications, Cadence Design Systems...	04-29
JPMorgan Downgrades ICON to Neutral From Overweight, Adjusts Price Target to $150 From $265	04-29	MT
BofA Securities Cuts Price Target on ICON to $204 From $255	04-14	MT
TD Cowen Downgrades ICON to Hold From Buy, Adjusts Price Target to $157 From $254	04-14	MT
Analyst recommendations: Apple, Blackstone, Estee Lauder, Mongodb, Stellantis…	04-14
Truist Adjusts ICON's Price Target to $208 From $262, Keeps Buy Rating	04-10	MT
Barclays Downgrades ICON to Equalweight From Overweight, Adjusts Price Target to $165 From $240	04-10	MT
Goldman Sachs Downgrades ICON to Neutral From Buy, Cuts Price Target to $200 From $250	03-21	MT
UBS Adjusts ICON Price Target to $250 From $290, Maintains Buy Rating	02-21	MT
Deutsche Bank Adjusts ICON Price Target to $235 From $250, Maintains Buy Rating	02-20	MT
Truist Securities Adjusts Price Target on ICON to $262 From $284, Keeps Buy Rating	02-13	MT
RBC Initiates ICON PLC at Outperform With $263 Price Target	01-07	MT
Truist Securities Adjusts Price Target on ICON to $284 From $295, Keeps Buy Rating	12-18	MT
Nephron Upgrades ICON to Buy, Price Target is $280	12-02	MT
Analyst recommendations: Five Below, Robinhood, Snowflake, Block, Ge Vernova...	11-25
UBS Adjusts Price Target on ICON to $290 From $380, Maintains Buy Rating	25/10/24	MT
Baird Downgrades ICON to Neutral From Outperform, Price Target is $340	24/10/24	MT
Analyst recommendations: P&G, Enphase, AT&T, Deckers Outdoor, ServiceNow...	24/10/24
Deutsche Bank Adjusts ICON Price Target to $360 From $370, Maintains Buy Rating	16/10/24	MT
Leerink Initiates ICON at Outperform With $379 Price Target	18/09/24	MT
Leerink Partners Initiates ICON at Outperform	18/09/24	MT
Truist Adjusts Price Target on ICON to $383 From $367, Maintains Buy Rating	26/07/24	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	ICON PUBLIC LIMITED COMPANY					+20.74%
	LONZA GROUP AG					+17.56%
	CELLTRION, INC.					+32.39%
	EUROFINS SCIENTIFIC SE					-0.01%
	QIAGEN N.V.					+5.55%
	Average					+15.25%
	Weighted average by Cap.					+18.36%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

146.48USD

Average target price

176.87USD

Spread / Average Target

+20.74%

High Price Target

243.00USD

Spread / Highest target

+65.89%

Low Price Target

144.00USD

Spread / Lowest Target

-1.69%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Truist Securities
Deutsche Bank Securities
JPMorgan Chase
BofA Securities
TD Cowen
Barclays
Goldman Sachs
UBS
RBC Capital Markets
Nephron Research
Baird
Leerink Partners
Evercore ISI
Mizuho Securities
Citigroup
Wells Fargo Securities
Morningstar
Guggenheim
Credit Suisse
Jefferies & Co.